Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
Amlodipine impurity 2 is a recognized impurity of the antihypertensive agent Amlodipine, primarily affecting the drug's quality and stability. Its presence is relevant for analytical chemistry and pharmaceutical development, particularly during the quality control of Amlodipine formulations. This compound serves as a critical reference standard for assessing purity and ensuring compliance with regulatory specifications in drug manufacturing processes. -
Drug Impurity
Terbinafine impurity 7 is a known impurity of the antifungal agent terbinafine. It serves as an important standard for analytical research and quality control in pharmaceutical development. The characterization and quantification of this impurity are essential for ensuring the safety and efficacy of terbinafine formulations. Its presence can affect the pharmacokinetics and overall therapeutic profile of the parent compound. -
Drug Impurity
Omeprazole impurity 4 is a known impurity of the proton pump inhibitor omeprazole. This compound can be utilized in the assessment of pharmaceutical purity, stability studies, and regulatory compliance for omeprazole formulations. Its characterization is essential for ensuring the safety and efficacy of proton pump inhibitor medications in clinical use. -
Drug Impurity
Dapagliflozin impurity 2 is a drug impurity associated with Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. This impurity is relevant for analytical chemistry applications and quality control processes in pharmaceutical research. Its characterization and quantification are important for ensuring the safety and efficacy of Dapagliflozin formulations in compliance with regulatory standards. -
Drug Impurity
Febuxostat impurity 5 is a known impurity associated with the drug febuxostat, which inhibits xanthine oxidase to reduce uric acid production. This compound is crucial for analytical and quality control studies, ensuring the purity of febuxostat formulations. Its characterization can aid in understanding the metabolic pathways and the overall safety profile of febuxostat in therapeutic applications. -
Drug Impurity
Aripiprazole impurity 28 is a characterized impurity of the antipsychotic agent Aripiprazole. This compound serves as a crucial analytical standard for the assessment of drug purity and stability in pharmaceutical formulations. Its presence may affect the pharmacokinetic and pharmacodynamic properties of the drug, making it integral for quality control and regulatory compliance in drug development studies. -
Drug Impurity
Estradiol benzoate impurity 4 is a minor impurity associated with Estradiol benzoate, a synthetic form of estrogen. This compound is significant for quality control purposes in pharmaceutical formulations and can be utilized in analytical chemistry to assess the purity of estradiol benzoate preparations. Its presence serves as a marker for the synthesis and handling processes in drug production. -
Drug Impurity
Sitagliptin impurity 14 is a chemical impurity associated with Sitagliptin, a DPP-4 inhibitor used in the treatment of type 2 diabetes. This impurity is relevant for the assessment of drug quality and stability in pharmaceutical development. It is essential for researchers focusing on the characterization and validation of drug compounds, ensuring compliance with regulatory standards in the production of therapeutic agents. -
Drug Impurity
Salmeterol impurity 11 is a known impurity associated with the bronchial antagonist Salmeterol. Its identification and quantification are crucial in the quality control of pharmaceutical products containing Salmeterol. Research applications include analytical method development and toxicological studies to ensure the safety and efficacy of therapeutic formulations. -
Drug Impurity
Dopamine Impurity 2 is a synthetic byproduct of dopamine, a key neurotransmitter involved in numerous neurological processes. This compound serves as a reference standard for assessing the purity of dopamine in research and pharmaceutical applications. Its characterization is essential for quality control and method development in drug formulation and analysis. -
Drug Impurity
Azilsartan impurity 3 is a characterized impurity of the antihypertensive agent Azilsartan. This compound may be utilized in quality control processes and analytical research to assess the purity of Azilsartan formulations. Its presence can influence the pharmacokinetics and overall efficacy of the drug, making it relevant in stability studies and regulatory assessments. -
Drug Impurity
Azithromycin impurity 11, also known as 3'-N-Demethyl-3'-N-formylazithromycin, represents a significant impurity of the antibiotic Azithromycin. This compound is essential for analytical studies and the assessment of drug purity in pharmacological research. Its presence can impact the efficacy and safety profile of Azithromycin, making it crucial for quality control in the pharmaceutical industry. -
Drug Impurity
Alfuzosin EP impurity 4 is a known impurity associated with the pharmaceutical compound Alfuzosin, a selective alpha-1 adrenergic antagonist. This reagent is essential for quality control and analytical characterization in the development and manufacturing processes of Alfuzosin. It is employed in research applications aimed at understanding impurities in drug formulations and ensuring compliance with pharmacopoeial standards. -
Drug Impurity
Terbinafine impurity 2 hydrochloride is a chemical impurity associated with Terbinafine hydrochloride, primarily serving as a reference standard in pharmaceutical research. Its identification and characterization are crucial for quality control and validation processes in drug development. This compound aids in assessing the purity of Terbinafine hydrochloride and ensuring compliance with regulatory standards. -
Drug Impurity
Erlotinib impurity 45 is a notable impurity associated with Erlotinib, a potent inhibitor of the epidermal growth factor receptor (EGFR). This compound serves as a reference standard in analytical chemistry for the evaluation of drug purity and quality control in pharmaceutical research. Its presence is critical for assessing the safety and efficacy profiles of Erlotinib-containing formulations in drug development and regulatory compliance. -
Drug Impurity
Mycophenolate impurity 6 is a known impurity associated with Mycophenolate. This compound serves as a reference standard for assessing the purity of Mycophenolate in pharmaceutical formulations. Its presence is critical for ensuring quality control and compliance with regulatory standards in drug development and manufacturing processes. -
Drug Impurity
Acebutolol impurity 3, also known as 2-Acetyl-4-butyramidophenol, is a recognized impurity associated with the pharmaceutical compound Acebutolol. This reagent is often utilized in analytical research to ensure the quality and purity of Acebutolol formulations. Its identification and characterization are crucial for compliance with regulatory standards in pharmaceutical development. -
Drug Impurity
Tenofovir impurity 19 is a characterized impurity of the antiviral compound Tenofovir, which acts as a nucleotide reverse transcriptase inhibitor. This impurity is critical for quality control and analytical purposes in pharmaceutical research and development. It aids in the assessment of the purity of Tenofovir formulations, ensuring compliance with safety and regulatory standards in drug manufacturing. -
Drug Impurity
Canagliflozin impurity 1 is a specific impurity associated with the SGLT2 inhibitor Canagliflozin, which targets sodium-glucose co-transporter 2 to facilitate glucose excretion. This compound is essential for understanding the metabolite profile and purity assessment of Canagliflozin in pharmaceutical formulations and research applications. Its characterization is crucial for ensuring the quality and efficacy of drug substances in regulatory compliance and safety evaluations. -
Drug Impurity
Tamsulosin impurity 10 is a known impurity associated with Tamsulosin, a selective alpha-1 adrenergic antagonist. It serves as an important reference standard for quality control and analytical studies in pharmaceutical research. Its characterization aids in understanding the purity and stability of Tamsulosin formulations, ensuring compliance with regulatory standards in drug development. -
Drug Impurity
Sitagliptin impurity 18 is a known impurity associated with the DPP-4 inhibitor Sitagliptin. This compound is critical for quality control and analytical research, providing insights into the purity and stability of Sitagliptin formulations. It is commonly used in pharmaceutical development and regulatory compliance studies to ensure that drug products meet necessary safety and efficacy standards. -
Drug Impurity
Estradiol Valerate impurity 4 is a known impurity associated with Estradiol Valerate, a hormone used in various therapeutic applications. Understanding this impurity is essential for ensuring the purity and safety of pharmaceutical formulations containing Estradiol Valerate. It serves as an important reference standard in drug development and quality control processes in the pharmaceutical industry. -
Drug Impurity
Rosuvastatin impurity 5 is a known impurity associated with the statin compound Rosuvastatin. This chemical is primarily utilized in the analytical evaluation of pharmaceutical formulations to ensure quality and compliance. Researchers employ Rosuvastatin impurity 5 in stability studies and impurity profiling, aiding in the development and regulatory assessment of therapeutic agents targeting cholesterol reduction. -
Drug Impurity
Ranitidine impurity 12 is a known impurity associated with the drug Ranitidine. It serves as a reference compound for the detection and quantification of impurities in pharmaceutical formulations. This compound is essential for quality control and compliance testing in drug development studies, particularly in the assessment of Ranitidine's purity and stability. Its analysis contributes to the overall understanding of the safety and efficacy of Ranitidine-containing products. -
Drug Impurity
Avatrombopag impurity 57 is a chemical impurity associated with Avatrombopag, a thrombopoietin receptor agonist. This impurity is critical for quality control and analytical studies in pharmaceutical research, ensuring the integrity and safety of Avatrombopag formulations. Its characterization supports the development and validation of analytical methods in the evaluation of drug purity and stability. -
Drug Impurity
Rivaroxaban impurity 22 is a chemical impurity associated with the anticoagulant Rivaroxaban. This compound is important for quality control and analytical studies in pharmaceutical research, particularly in assessing the purity and stability of Rivaroxaban formulations. Its characterization can aid in understanding the metabolic pathways and potential side effects of Rivaroxaban, contributing to the advancement of drug safety and efficacy studies. -
Drug Impurity
Azilsartan impurity 9, also known as Azilsartan impurity H, is a chemical reagent classified as a drug impurity of Azilsartan. It is utilized primarily for quality control and analytical applications in pharmaceutical research, particularly in the analysis of drug formulations. Understanding and quantifying impurities like Azilsartan impurity 9 is essential for ensuring the safety and efficacy of pharmaceutical products. -
Drug Impurity
Roflumilast impurity 2 is a chemical byproduct associated with Roflumilast, a phosphodiesterase-4 (PDE4) inhibitor. This impurity is significant for analytical and quality control studies in pharmaceutical research, ensuring the integrity and safety of formulations containing Roflumilast. Its identification and quantification are essential for regulatory compliance and the development of therapeutic applications. -
Drug Impurity
Tacrolimus impurity 5 is a known impurity of the immunosuppressant drug Tacrolimus, which targets the protein phosphatase Calcineurin. This reagent can be utilized in analytical chemistry for the characterization and quantification of Tacrolimus formulations. Its study is important for ensuring the quality and safety of pharmaceutical products involving Tacrolimus. -
Drug Impurity
Canagliflozin tetraacetate is a chemical impurity associated with the SGLT2 inhibitor Canagliflozin. It is primarily used as a reference standard for analytical and quality control purposes in pharmaceutical research. The identification and quantification of this impurity are important for evaluating the purity and safety profiles of Canagliflozin in drug development and formulation studies. -
Drug Impurity
Tenofovir isoproxil monoester is a drug impurity of interest primarily in the synthesis and quality control of antiviral medications. This compound serves as a critical marker in pharmacokinetic studies and can be utilized in analytical applications to ensure the integrity and safety of Tenofovir formulations. It plays a significant role in the assessment of drug purity and regulatory compliance within pharmaceutical research. -
Drug Impurity
4-(2-(tert-Butylamino)ethyl)-2-methylphenol, also known as Salbutamol Impurity, is a known impurity of the bronchodilator Salbutamol. This compound serves as a critical reference standard for the identification and quantification of impurities in pharmaceutical formulations. Its detection is essential in ensuring the purity and quality of Salbutamol during analytical assessments in drug development and manufacturing processes. -
Drug Impurity
Levofloxacin impurity 11 is a synthetic impurity associated with Levofloxacin. This compound serves as an important analytical standard for quality control in pharmaceutical research and development. Its characterization is critical for ensuring the purity and efficacy of Levofloxacin formulations, contributing to the overall safety profile of the drug in clinical applications. -
Drug Impurity
Salbutamol impurity 8 (N-Benzyl albuterol) is a chemical impurity associated with the pharmaceutical agent Salbutamol. It serves as a reference standard for the identification and quantification of impurities during quality control processes in drug development and manufacturing. This compound is essential for ensuring the safety and efficacy of Salbutamol formulations in respiratory therapeutic applications. -
Drug Impurity
Clindamycin palmitate impurity 7, also known as Clindamycin stearate, is a characterized drug impurity associated with clindamycin formulations. It is primarily relevant in the assessment of drug purity and quality control processes. This compound is utilized in pharmaceutical research and development to ensure the integrity and safety of antibiotic formulations, providing critical insights into impurity profiles and their potential impact on therapeutic efficacy. -
Drug Impurity
Budesonide impurity 85, also known as 21-Dehydro budesonide, is a drug impurity associated with the corticosteroid Budesonide. This compound serves as an important analytical standard for quality control in pharmaceutical formulations. Its examination is critical for ensuring the purity of Budesonide products and for assessing their safety and efficacy in clinical applications. -
Drug Impurity
Apixaban Impurity 19 is a chemical impurity associated with the anticoagulant drug Apixaban. This compound is critical for quality control and analytical studies in pharmaceutical research, enabling researchers to assess the purity and safety of Apixaban formulations. It serves as a reference standard for method validation and impurity profiling in drug development and compliance testing. -
Drug Impurity
Alfacalciferol impurity 1 is a characterized impurity associated with the active form of vitamin D, Alfacalciferol. This compound is relevant in the assessment of drug purity and quality control in pharmaceutical formulations that contain Alfacalciferol. Its presence can be significant in understanding the pharmacokinetics and metabolic pathways of vitamin D compounds in biological research. -
Drug Impurity
Betamethasone valerate impurity 2 is a drug impurity associated with Betamethasone valerate. It serves as an important marker for quality control and characterization in pharmaceutical formulations. Its identification and analysis are crucial for ensuring the purity and safety of corticosteroid products used in various therapeutic applications. -
Drug Impurity
Ketoprofen Impurity 1 is a known impurity of the non-steroidal anti-inflammatory drug (NSAID) Ketoprofen. It serves as a valuable standard for quality control and analytical applications in pharmaceutical research. Studying this impurity aids in understanding the metabolic profile and potential degradation pathways of Ketoprofen, ensuring the integrity of formulations containing this compound. -
Drug Impurity
Levetiracetam impurity 3 is a chemical impurity associated with the anticonvulsant drug Levetiracetam. This impurity may be utilized in analytical chemistry studies to assess the purity and stability of Levetiracetam formulations. It is valuable for researchers analyzing drug composition and conducting quality control assessments in pharmaceutical development. -
Drug Impurity
Alfuzosin EP impurity 1 hydrochloride, also known as 2,3,4,5-Tetradehydro alfuzosin hydrochloride, is a recognized impurity of Alfuzosin hydrochloride. This compound is essential for evaluating the purity and stability of alfuzosin formulations in pharmaceutical development. Researchers may utilize this impurity in studies assessing drug quality, pharmacokinetics, and mechanism of action related to alpha-1 adrenergic receptor antagonism. -
Drug Impurity
Imatinib impurity 21 is a known impurity related to the tyrosine kinase inhibitor Imatinib. This compound serves as an important reference standard in analytical chemistry to evaluate the purity and stability of Imatinib formulations. Its analysis is critical for ensuring compliance with regulatory standards in the pharmaceutical industry and for assessing potential biological impacts in drug safety studies. -
Drug Impurity
Azilsartan impurity 31 is a known impurity associated with Azilsartan, an angiotensin II receptor antagonist. This compound is primarily used in pharmaceutical research to ensure the quality and purity of Azilsartan formulations. Its characterization is crucial for regulatory compliance and assessment of potential effects in drug safety evaluations. -
Drug Impurity
Losartan impurity 19, also known as N1-Losartanyl-losartan, is a specific impurity associated with the angiotensin II receptor antagonist Losartan. This compound is used primarily for analytical purposes in quality control and characterization of Losartan formulations. It aids in the assessment of the purity and stability of Losartan products, ensuring compliance with regulatory standards in pharmaceutical research and development. -
Drug Impurity
Levothyroxine impurity 14, also known as 3-Chloro-3’,5,5’-triiodo-L-thyronine, is classified as a drug impurity. This compound may arise during the synthesis or degradation of levothyroxine and is essential for assessing the purity and quality of pharmaceutical formulations. Its identification and quantification are critical in ensuring product safety and efficacy in thyroid hormone therapies. -
Drug Impurity
Crizotinib impurity 1 is a noted impurity associated with the targeted therapy Crizotinib, primarily acting on the anaplastic lymphoma kinase (ALK) and c-MET pathways. This compound is essential for assessing the purity of Crizotinib formulations in pharmaceutical development and quality control. Its analysis is crucial for ensuring compliance with regulatory standards related to drug safety and efficacy. -
Drug Impurity
Levofloxacin impurity 8 is a known impurity of the antibiotic Levofloxacin. It serves as a critical reference standard for assessing the purity and quality of pharmaceutical formulations containing Levofloxacin. This compound is essential for analytical studies and regulatory compliance, particularly in the development and quality control of antibacterial drugs. -
Drug Impurity
Olmesartan Impurity 5 is a chemical byproduct associated with the synthesis of Olmesartan, an antihypertensive agent. This impurity serves as a reference standard for quality control and regulatory compliance in pharmaceutical research. It is critical for analytical method development and validation, ensuring the purity and safety of Olmesartan in drug formulations. -
Drug Impurity
Donepezil impurity 13 is a chemical impurity associated with Donepezil, a reversible inhibitor of acetylcholinesterase. It serves as an important reference standard in analytical chemistry for the assessment of pharmaceutical purity. This compound is utilized in the quality control and stability testing of Donepezil formulations, ensuring compliance with regulatory standards in drug development and manufacturing processes.
